HIV associated hypocalcaemia among diarrheic patients in northwest Ethiopia: a cross sectional study

BMC Public Health

Afework Kassu⁴  Timoki Yabutani²  Bemnet Amare¹  Beyene Moges³ 

[1] Department of Biochemistry, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia;Department of Chemical Engineering, University of Tokushima, Tokushima, Japan;Department of Immunology and Molecular Biology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia;Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

关键词: Ethiopia;    Diarrhea;    HIV;    Hypercalcaemia;    Hypocalcaemi;   

Others  :  866318
DOI  :  10.1186/1471-2458-14-679

 received in 2014-01-07, accepted in 2014-06-27,  发布年份 2014

【 摘 要 】

Background

Hypocalcaemia, defined by serum calcium level less than 8.5 mg/dl, could be caused by human immunodeficiency virus (HIV) and diarrheal diseases. In Ethiopia, while morbidities from diarrheal diseases and HIV are serious health problems, studies assessing the interactions amongst of the three do not exist. Therefore, the present study was undertaken to investigate the level of calcium among diarrheic patients with and without HIV co-infection.

Methods

Consecutive diarrheic patients attending Gondar University Hospital in Ethiopia were enrolled and screened for HIV, intestinal parasites, Shigella and Salmonella. Concentration of calcium in serum was determined using an inductively coupled plasma mass spectrometer.

Results

A total of 206 diarrheic patients were included in the study (109 = HIV positive, 97 = HIV negative). Intestinal parasites and Shigella species were detected in 32.2% and 8.5% of the patients, respectively. The serum calcium levels in the patients who were found positive for Shigella species or intestinal parasites was not significantly different by the presence or absence of HIV co-infection. HIV infected diarrheic patients had significantly lower mean serum calcium levels (7.82 ± 1.23 mg/dl) than those negative for HIV (8.38 ± 1.97) (P = 0.015). The age groups 25–35 and greater than 45 years showed significantly lower mean serum calcium levels (7.77 ± 1.55 mg/dl) in comparison to the other age groups (7.84 ± 1.41 mg/dl, P = 0.009). On the other hand, females presented with significantly lower mean serum calcium levels (7.79 ± 1.60 mg/dl, P = 0.044) than males (8.26 ± 1.65 mg/dl).

Conclusion

There is high prevalence of hypocalcaemia among diarrheic patients in northwest Ethiopia. And HIV stood out to be a major risk factor for development of hypocalcaemia among the diarrheic patients in northwest Ethiopia. Further studies are required to substantiate and characterize the mechanisms and consequences of calcium metabolism disorders among HIV infected individuals in the study area.

【 授权许可】

   
2014 Moges et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Pond K, Rueedi J, Microrisk S: Pathogens in Drinking Water Sources. University of Surrey, UK: Robens Centre for Public and Environmental Health; 2004.
• [2]Asghar U, Saba N, Samad A, Qazilbash AA: Identification, Characterization and Antibiotic susceptibility of Salmonella and Shigella Species Isolated from Blood and Stool samples of Patients N.I.H, Islamabad. J Med Sci 2002, 2:85-88.
• [3]World Health Organization (WHO): Fifty-fourth World Health Assembly. Assembly documents. Provisional agenda item 13.3: Communicable diseases. Control of schistosomiasis and soil-transmitted helminth infections. Geneva: Report by the secretariat; 2001.
• [4]Kosek M, Bern C, Guerrant RL: The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003, 81:197-204.
• [5]AIDS epidemic update: Special report on HIV prevention. Joint United Nations Program on HIV/AIDS/World Health Organization (UNAIDS/WHO). Geneva: UNAIDS/WHO; 2005.
• [6]Siddiqui U, Bini EJ, Chandarana K, Leong J, Ramsetty S, Schiliro D, Poles M: Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy. J Clin Gastroenterol 2007, 41:484.
• [7]Call SA, Heudebert G, Saag M, Wilcox CM: The changing etiology of chronic diarrhea in HIV-infected patients with CD4 cell counts less than 200 cells/mm3. Am J Gastroenterol 2000, 95:3142.
• [8]Durrer P, Zbinden R, Fleisch F, Altwegg M, Ledergerber B, Karch H, Weber R: Intestinal infection due to enteroaggregative Escherichia coli among human immunodeficiency virus-infected persons. J Infect Dis 2000, 182:1540.
• [9]Knox TA, Spiegelman D, Skinner SC, Gorbach S: Diarrhea and abnormalities of gastrointestinal function in a cohort of men and women with HIV infection. Am J Gastroenterol 2000, 95:3482.
• [10]World Health Organization (WHO): Provisional WHO clinical case definition for AIDS. Wkly Epidemiol Rec 1986, 10:303-306.
• [11]Glassock RJ, Cohen AH, Danovitch G, Parsa KP: Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med 1990, 112:35.
• [12]Vitting KE, Gardenswartz MH, Zabetakis PM, Tapper ML, Gleim GW, Agrawal M, Michelis MF: Frequency of hyponatremia and nonosmolar vasopressin release in the acquired immunodeficiency syndrome. JAMA 1990, 263:973.
• [13]Tang WW, Kaptein EM, Feinstein EI, Massry SG: Hyponatremia in hospitalized patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex. Am J Med 1993, 94:169.
• [14]Peter SA: Electrolyte disorders and renal dysfunction in acquired immunodeficiency syndrome patients. J Natl Med Assoc 1991, 83:889-891.
• [15]Kalin MF, Poretsky L, Seres DS, Zumoff B: Hyporeninemic hypoaldosteronism associated with acquired immune deficiency syndrome. Am J Med 1987, 82:1035.
• [16]Guy RJ, Turberg Y, Davidson RN, Finnerty G, MacGregor GA, Wise PH: Mineralocorticoid deficiency in HIV infection. BMJ 1989, 298:496.
• [17]Choi MJ, Fernandez PC, Patnaik A, Coupaye-Gerard B, D'Andrea D, Szerlip H, Kleyman TR: Brief report: trimethoprim-induced hyperkalemia in a patient with AIDS. N Engl J Med 1993, 328:703.
• [18]Greenberg S, Reiser IW, Chou SY, Porush JG: Trimethoprim-sulfamethoxazole induces reversible hyperkalemia. Ann Intern Med 1993, 119:291.
• [19]Velázquez H, Perazella MA, Wright FS, Ellison DH: Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993, 119:296.
• [20]Chattha G, Arieff AI, Cummings C, Tierney LM Jr: Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med 1993, 118:37.
• [21]Isnard Bagnis C, Du Montcel ST, Fonfrede M, Jaudon MC, Thibault V, Carcelain G, Valantin MA, Izzedine H, Servais A, Katlama C, Deray G: Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol 2006, 103:131.
• [22]Emejulu AA, Onwuliri VA, Ojiako OA: Electrolyte Abnormalities and Renal Impairment in Asymptomatic HIV-infected Patients in Owerri, South Eastern Nigeria. Aust J Basic Appl Sci 2011, 5(3):257-260. ISSN 1991–8178
• [23]Kuehn EW, Anders HJ, Bogner JR, Obermaier J, Goebel FD, Schlöndorff D: Hypocalcaemia in HIV infection and AIDS. J Intern Med 1999, 245:69-73.
• [24]Bemnet A, Solomon M, Tomoki Y, Beyene M, Afework K: Hypercalcemia in Patients with Tuberculosis and HIV Infections in Northwest Ethiopia. Asian Pac J Trop Dis 2012, 1-6.
• [25]Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board, Institute of Medicine: Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press; 2010.
• [26]Amaresh Reddy P, Harinarayan CV, Suresh V, Rajagopal G, Krishna Tilak T, Suchitra MM, Srinivasa Rao PVLN, Sachan A, Kalawat TC: Effect of block-replacement regimen on bone mineral density and biochemical markers in patients with thyrotoxic bone disease. J Clin Sci Res 2012, 1:60-70.
• [27]Riccardi D, Brown EM: Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am J Physiol Renal Physiol 2010, 298:F485.
• [28]Strauss KW: Endocrine complications of the acquired immunodeficiency syndrome. Arch Intern Med 1991, 151:1441]4.
• [29]Peter SA: Disorders of serum calcium in acquired immunodeficiency syndrome. J Natl Med Assoc 1992, 84:626]8.
• [30]Poretsky L, Maran A, Zumoff B: Endocrinologic and metabolic manifestations of the acquired immunodeficiency syndrome. Mt Sinai J Med 1990, 57:236]41.
• [31]Cheesbrough M: District Laboratory Practice in Tropical Countries. Escherichia coli. Part II. 2nd edition. UK: Cambridge University Press; 2006:178-179.
• [32]Cheesbrough M: District laboratory practice in tropical countries. parasitological tests. Part I. 2nd edition. UK: Cambridge University Press; 2005:200-208.
• [33]Mulu A, Kassu A, Huruy K, Tegene B, Yitayaw G, Nakamori M, Van Nhien N, Bekele A, Wondimhun Y, Yamamoto S, Ota F: Vitamin A deficiency during pregnancy of HIV infected and non-infected women in tropical settings of Northwest Ethiopia. BMC Public Health 2011, 11:569. BioMed Central Full Text
• [34]Voica C, Dehelean A, Iordache A, Geana I: Method Validation For Determination Of Metals In Soils By ICP-MS. Rom Rep in Phy 2012, 64:221-231.
• [35]Pieter E, Bert B, Kathleen C, Dirk K, Bjorn M, Yves V: Measuring Total Blood Calcium Displays a Low Sensitivity for the Diagnosis of Hypercalcemia in Incident Renal Transplant Recipients. Clin J Am Soc Nephrol 2010, 5:2085-2092.
• [36]Glassoc RJ, Cohen AH, Danovitch G, Parsa KP: Human immunodeficiency virus (HIV) infection and the kidney. Ann Intern Med 1992, 112:35-49.
• [37]Grinspoon SK, Bilezikian JP: HIV disease and the endocrine system. N Engl J Med 1992, 327:1360-1365.
• [38]Perazella MA, Brown E: Electrolyte and acid–base disorders associated with AIDS. J Gen Intern Med 1994, 9:232-236.
• [39]Jacobsen MA, Gambertoglio JG, Aweeka FT, Causey DM, Portale AA: Foscarnet induced hypocalcaemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab 1991, 72:1130-1135.
• [40]Sellmeyer DE, Grunfeld C: Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 1996, 17:518-532.
• [41]Hofbauer LC, Heufelder AE: Endocrine implications of human immunodeficiency virus infection. Medicine 1996, 75:262-278.
• [42]Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14(4):F63-F67. PubMed: 10770534
• [43]Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M, Tebas P: Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus–infected individuals. Clin Infect Dis 2003, 36(4):482-490. PubMed: 12567307
• [44]Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292(2):191-201. PubMed: 15249568
• [45]Overton E, Mondy K, Bush T, Conley LJ, Kojic EM, Henry K, Hammer J, Wood KC, Lichtenstein KA, Brooks JT, SUN Study Investigators: Factors associated with low bone mineral density (BMD) in a chort of HIV-Infected U.S. adults—baseline results from the SUN study abstract 836]. Los Angeles, CA: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; 2007.
• [46]Tebas P, Umbleja T, Dube M: Initiation of ART is associated with bone loos independent of the specific ART regimen: Results of ACTG A5005s [abstract 837]. Los Angeles, CA: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 2007.
• [47]Fakruddin JM, Laurence J: HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005, 150(1):67-78. PubMed: 15449141
• [48]Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL: The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15:2-12.
• [49]Fauci AS: Host factors and the pathogenesis of HIV induced disease. Nature 1996, 384:529-534.
• [50]Manolagas SC, Jilka RL: Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995, 332:305-311.
• [51]Kong Y-Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
• [52]Horwood NJ, Kartsogiannis V, Quinn JMW, Romas E, Martin TJ, Gillepsie MT: Activated T cells support osteoclast formation in vitro. Biochem Biophys Res Commun 1999, 265:144-150.
• [53]Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T: Tumor necrosis factor-a stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKLRANK interaction. J Exp Med 2000, 191:275-286.
• [54]Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA, Suda T: Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp Cell Res 1999, 247:84-93.
• [55]Canaff L, Hendy GN: Calcium-sensing receptor gene transcription is up-regulated by the proinflammatory cytokine, interleukin-1β. J Biol Chem 2005, 280:14177-14188.
• [56]Lind L, Carlstedt F, Rastad J, Stiernström H, Stridsberg M, Ljunggren O, Wide L, Larsson A, Hellman P, Ljunghall S: Hypocalcaemia and parathyroid hormone secretion in critically ill patients. Crit Care Med 2000, 28:93-99.
• [57]Boyce BF, Yates AJP, Mundy GR: Bolus injections of recombinant human interleukin-1 cause transient hypocalcaemia in normal mice. Endocrinology 1989, 125:2780-2783.
• [58]Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 1996, 87:2095-2147.
• [59]Deng X, Oguri S, Funayama H, Ohtaki Y, Ohsako M, Yu Z, Sugawara S, Endo Y: Prime role of bone IL-1 in mice may lie in emergency Ca2 + −supply to soft tissues, not in boneremodeling, Int Immunopharmacol. 14 2012, 658(4):664.
• [60]Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis Am J Med 1993, 94(6):646-650.
• [61]Ross PD, Davis JW, Epstein RS, Wasnich RD: Preexisting fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991, 114:919-923.
• [62]Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, Oden A, Zethraeus N, Pfleger B, Khaltaev N: Assessment of fracture risk. Osteoporos Int 2005, 16:581-589.
• [63]Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE: HIV infection and bone mineral density in middleaged women. Clin Infect Dis 2006, 42(7):1014-1020.
• [64]Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A, Keller MJ: Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 2008, 19(7):913-918.
• [65]Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, Manandhar M, Addesso V, Shane E: Bone mass and mineral metabolism in HIV + postmenopausal women. Osteoporos Int 2005, 16(11):1345-1352.
• [66]Mora S, Gilsanz V: Establishment of peak bone mass. Endocrinol Metab Clin North Am 2003, 32(1):39-63.
• [67]Orwoll ES, Klein RF: Osteoporosis in men. Endocr Rev 1995, 16:87-116.
• [68]Ahmed B, Jaspan JB: Case report: hypercalcemia in a patient with AIDS and Pneumocystis carinii pneumonia. Am J Med Sci 1993, 306:313-316.
• [69]Playford EG, Bansal AS, Looke DF, Whitby M, Hogan PG: Hypercalcemia and elevated 1,25(OH)(2)D(3) levels associated with disseminated Mycobacterium avium infection in AIDS. J Infect 2001, 42(2):157-158.
• [70]Cheungpasitporn W, Suksaranjit P, Chanprasert S: Hypercalcemia in Human Immunodeficiency Virus-Related Lymphoma and Valacyclovir Toxicity. Am J Med Sci 2011, 342:539.
• [71]Joshua F, Douglas W, Parviz H, Leonard JD: Hypercalcemia in Disseminated Coccidioidomycosis; Expression of PTHrP is Characteristic of Granulomatous Inflammation. Clin Infect Dis 2012, 55(7):61-66.
• [72]Melissa K, Francis G, Martin H, Christopher W, Gregory K: Rare Causes of Calcitriol-Mediated Hypercalcemia: A Case Report and Literature Review. J Clin Endocrinol Metab 2010, 95:3111-3117.
• [73]Rafael MA, Loureno C, Daniela MT, de CF MA, Mário José AS: Hypercalcemia in a patient with disseminated paracoccidioidomycosis: a case report. J Med Case Rep 2008, 2:262. BioMed Central Full Text
• [74]Sadeghian MH, Ayatollahi H, Keramati MR, Memar B, Jamedar SA, Avval MM, Sheikhi M, Shaghayegh G: The association of Epstein - Barr virus infection with multiple myeloma. Indian J Pathol Microbiol 2011, 54:720-724.
• [75]Lawn SD, Macallan DC: Hypercalcemia: a manifestation of immune reconstitution complicating tuberculosis in an HIV-infected person. Clin Infect Dis 2004, 38:154-155.
• [76]Ferrand RA, Elgalib A, Newsholme W, Childerhouse A, Edwards SG, Miller RF: Hypercalcaemia complicating immune reconstitution in an HIV-infected patient with disseminated tuberculosis. Int J STD AIDS 2006, 17:349-350.
• [77]Feleke Y, Abdulkadir J, Mshana R, Mekbib TA, Brunvand L, Berg JP, Falch JA: Low levels of serum calcidiol in an African population compared to a North European population. Euro J of Endocrin 1999, 141:358-360.
• [78]Barbara AG: Sun exposure and vit D sufficiency. Clin Nutr 2008, 88:570S-577S.